Christian Bruehlmann has been Chief Strategy Officer since December 2023. He was CBO and co-founder of Proteomedix AG, a Swiss healthcare company whose mission is to transform prostate cancer diagnosis, which was acquired by the Company in December 2023. Mr. Bruehlmann gained 20 years of experience in public and private companies in the life sciences, information and communications (ICT) and financial industries. Being responsible for product management, business development, operations and finance, he was instrumental in Proteomedix’ development from inception to the market introduction of the lead product Proclarix, a blood based prostate cancer test panel and risk score currently available in Europe and exclusively out-licensed to LabCorp for the US. Previously, he worked for Swisscom, Switzerland's telecom market leader in several strategic and leadership roles in the area of digitalization. Mr. Bruehlmann received his Bachelor and Master in Business Administration from University of Zurich, Switzerland and completed executive professional trainings at the Babson College, USA and at the University of St. Gallen, Switzerland.